Merck, Schering delay earnings for Vytorin update
NEW YORK (Reuters) - Merck & Co and Schering-Plough said they would delay release of company earnings until after the stock market closes on Monday, in order to update investors on a new important study of their shared Vytorin cholesterol fighter.
<p><img src="http://feeds.reuters.com/~a/reuters/businessNews?i=V4sLI2" border="0"></img> (http://feeds.reuters.com/~a/reuters/businessNews?a=V4sLI2)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/businessNews?i=iSPCJJ" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=iSPCJJ) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=nWiraj" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=nWiraj) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=5N6wtj" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=5N6wtj)
</div><img src="http://feeds.reuters.com/~r/reuters/businessNews/~4/341463781" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/341463781/idUSN2133987320080721